Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in advanced gastric or gastro-esophageal junction cancer
NCT01585987Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2012
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of ipilimumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Bristol Myers Squibb. Started Jul 2012; status: completed.
02
Drugs
ipilimumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01585987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585987.